Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 302 E Pettigrew St Ste A100 DURHAM NC 27701-2393 |
Tel: | N/A |
Website: | https://precisionbiosciences.com |
IR: | See website |
Key People | ||
Michael Amoroso President, Chief Executive Officer, Director | Alex Kelly Chief Financial Officer | Dario Scimeca General Counsel, Secretary |
Alan List Chief Medical Officer | Jeff Smith Chief Research Officer |
Business Overview |
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision. ARCUS particularly generates defined outcomes due to predominant repair using homology directed repair (HDR) as opposed to non-homologous end joining (NHEJ). The Company's in vivo gene editing programs include PBGENE-HBV, PBGENE-PMM, PBGENE-NVS, PBGENE-DMD, PBGENE-LL2, PBGENE-LL3 and iECURE-OTC. PBGENE-HBV program is designed for the potential treatment of chronic hepatitis B virus (HBV). The Company is pursuing development of PBGENE-PMM as a potential opportunity for treatment of m.3243 associated primary mitochondrial myopathy (PMM). |
Financial Overview |
For the fiscal year ended 31 December 2023, Precision BioSciences Inc revenues increased 94% to $48.7M. Net loss before extraordinary items decreased 42% to $42.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Impairment CHarges decrease from $10.8M (expense) to $0K, Interest income increase from $3.5M to $7.7M (income). |
Employees: | 109 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $48.73M as of Dec 31, 2023 |
EBITDA (TTM): | -$36.92M as of Dec 31, 2023 |
Net annual income (TTM): | -$42.53M as of Dec 31, 2023 |
Free cash flow (TTM): | -$86.39M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 6,916,239 as of Mar 21, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |